Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

Publication ,  Journal Article
Pollyea, DA; Bixby, D; Perl, A; Bhatt, VR; Altman, JK; Appelbaum, FR; de Lima, M; Fathi, AT; Foran, JM; Gojo, I; Hall, AC; Jacoby, M; Mims, A ...
Published in: J Natl Compr Canc Netw
January 6, 2021

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 6, 2021

Volume

19

Issue

1

Start / End Page

16 / 27

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Mutation
  • Leukemia, Myeloid, Acute
  • Humans
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., … Tallman, M. S. (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw, 19(1), 16–27. https://doi.org/10.6004/jnccn.2021.0002
Pollyea, Daniel A., Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, et al. “NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.J Natl Compr Canc Netw 19, no. 1 (January 6, 2021): 16–27. https://doi.org/10.6004/jnccn.2021.0002.
Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 Jan 6;19(1):16–27.
Pollyea, Daniel A., et al. “NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.J Natl Compr Canc Netw, vol. 19, no. 1, Jan. 2021, pp. 16–27. Pubmed, doi:10.6004/jnccn.2021.0002.
Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival M-E, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 Jan 6;19(1):16–27.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 6, 2021

Volume

19

Issue

1

Start / End Page

16 / 27

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Mutation
  • Leukemia, Myeloid, Acute
  • Humans
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis